A cross-sectional study using the Surveillance, Epidemiology, and End Results Program database to estimate the prevalence of Myelodysplastic syndrome (MDS) in the United States

Myelodysplastic syndrome (MDS) is a hematologic disorder characterized by ineffective blood cell production leading to cytopenias and a propensity for progression to acute myeloid leukemia (AML). In this study, we aimed to assess the prevalence of MDS in the United States population using data from the Surveillance, Epidemiology, and End Results (SEER) database. Our analysis revealed that the highest prevalence of MDS was observed in the over 85 age group, with an overall prevalence rate of 0.02%. Furthermore, our findings indicated that the White race had the highest prevalence rate compared to other racial groups. However, it should be noted that the SEER database, most likely due to sampling biases, has a potential underestimation of minority populations, but SEER and the US population are statistically similar enough for comparison. These results suggest a need for further research on the underlying factors contributing to the prevalence of MDS in the United States population; factors such as genetic, environmental, comorbidities, and racial disparities should be explored. Early diagnosis and treatment of MDS are crucial for improving outcomes for patients with this condition.